Cas:5021-47-6 2-Phenyl-1,2,3,4-tetrahydroquinoxaline manufacturer & supplier

Chemical Name:2-Phenyl-1,2,3,4-tetrahydroquinoxaline

CAS.NO:5021-47-6

Synonyms:2-phenyl-1,2,3,4-tetrahydroquinoxaline

Molecular Formula:C₁₄H₁₄N₂

Molecular Weight:210.27400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:395.453ºC at 760 mmHg

Density:1.092g/cm3

Index of Refraction:1.59

PSA:24.06000

Exact Mass:210.11600

LogP:3.54130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2811 6.1 / PGIII

Packing Group:

Contact us for information like 2-phenyl-1,2,3,4-tetrahydroquinoxaline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-phenyl-1,2,3,4-tetrahydroquinoxaline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-phenyl-1,2,3,4-tetrahydroquinoxaline Use and application,2-phenyl-1,2,3,4-tetrahydroquinoxaline technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2-Phenyl-1,2,3,4-tetrahydroquinoxaline manufacturer Beneficial drug raw materials refer to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs). They are mainly used to meet the needs of original multinational pharmaceutical companies and emerging biopharmaceutical companies for innovative drugs in clinical drug research, registration approval and commercialization sales , Which also contains advanced intermediates used in the manufacture of the drug substance that need to be regulated by regulatory authorities. 2-Phenyl-1,2,3,4-tetrahydroquinoxaline supplier Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. 2-Phenyl-1,2,3,4-tetrahydroquinoxaline vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2-Phenyl-1,2,3,4-tetrahydroquinoxaline factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.